[Key points of nursing HbeAg negative cirrhotic patients with nucleot (s) ide analogues antiviral therapy].

OBJECTIVE: To explore the key points of nursing HBeAg negative cirrhotic patients with nucleot(s) ide analogues antiviral therapy.

METHOD: Patients enrolled into this study were divided into antiviral group (58 cases) and control group (53 cases). Patients from control group only received the supportive and symptomatic treatment and those from antiviral group received the additional nucleot (s) ide analogues treatment. All patients were observed during hospitalization and were followed up in clinic. Finally, we would make a nursing assessment.

RESULTS: All patients finished the 96-week treatment and follow-up, except 6 patients died. Alanine transferase normalization rate and HBV DNA decline were more remarkable in antiviral group than that in control group. HBV DNA negative( <500 copies/ml) after 96-week treatment were 88.7% in antiviral group and 32. 5% in control group respectively(Chi(2) = 31.427, P = 0.001).

CONCLUSION: Nucleot(s) ide analogues are significantly effective to inhibit HBV DNA replication in HBeAg negative cirrhotic patients and improve liver function. The key points of nursing these patients including appropriate patients' educating, benign nurse-patient relationship building, medical compliance emphasizing, and attentive complication observing and dealing.